Sophia Genetics SA (SOPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sophia Genetics SA (SOPH) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.79 Million) by net assets ($60.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SOPH equity to assets ratio to measure how much of total assets are equity-financed.
Sophia Genetics SA - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Sophia Genetics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore SOPH long-term investment intensity to see how much of total assets are deployed in long-term investments.
Sophia Genetics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sophia Genetics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wildcat Resources Ltd
AU:WC8
|
-0.002x |
|
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
SHE:002864
|
0.016x |
|
New Providence Acquisition Corp. III Class A Ordinary Shares
NASDAQ:NPAC
|
-0.001x |
|
Everyday Network
SHE:300295
|
0.074x |
|
IMC SA
WAR:IMC
|
0.019x |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
0.007x |
|
PI Advanced Materials Co. Ltd
KQ:178920
|
0.051x |
|
Ideal Group S.A
AT:INTEK
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Sophia Genetics SA (2019–2024)
The table below shows the annual cash flow conversion efficiency of Sophia Genetics SA from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Sophia Genetics SA (SOPH) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $96.49 Million | $-42.82 Million | -0.444x | -38.36% |
| 2023-12-31 | $151.44 Million | $-48.58 Million | -0.321x | +8.42% |
| 2022-12-31 | $200.13 Million | $-70.09 Million | -0.350x | -66.48% |
| 2021-12-31 | $275.40 Million | $-57.94 Million | -0.210x | +33.36% |
| 2020-12-31 | $100.51 Million | $-31.73 Million | -0.316x | +77.82% |
| 2019-12-31 | $22.25 Million | $-31.68 Million | -1.424x | -- |
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutic… Read more